London, England -- (SBWire) -- 11/16/2010 -- North America and Europe represents the largest markets worldwide for H1N1 Vaccines, as stated by the new market research report on H1N1 Vaccines. Robust sales growth experienced during initial period will substantially decrease with passing year, with great proportion of the global population getting vaccination against the pandemic virus. With pandemic situation easing in several countries demand for H1N1 vaccines is expected to gradually recede, specifically in the US, Europe, and Canada. Intramuscular vaccines or flu shots account for majority of market revenues, followed by intranasal vaccines.

The report titled H1N1 Vaccines: A Global Strategic Business Report, provides a comprehensive review on the global H1N1 pandemic situation, regional data, statistical review of confirmed and suspected cases by region, deaths by region, the H1N1 vaccines availability, the manufacturers involved, current market analysis, future prospects, vaccines availability across different regions, disease overview, regulatory approvals, recent industry activity, and focus on key market participants. The study analyzes market data and analytics in terms of value sales for regions including the United States, Europe, Asia-Pacific, and Rest of World.

The world market for H1N1 Vaccines is projected to reach $544.3 million by 2015. With the World Health Organization declaring H1N1 influenza as pandemic in 2009, H1N1 vaccines emerged as a vital tool to combat the infection and to protect thousands of people against the deadly disease. Increased awareness among people regarding the pandemic situation contributed for overwhelming growth of H1N1 vaccines during 2009. These vaccines have been so far successful in easing pandemic outbreak in several countries.

Backed by public health measures and continuing vaccination campaigns around the world, the rate of transmission of H1N1 virus, colloquially called swine flu, is slowing gradually with the pandemic situation easing in many countries. Presently, the H1N1 pandemic is referred to be "moderately" severe, since majority of individuals had been vaccinated against the virus and significant proportion of patients experiencing fast recovery.

Key players profiled in the report include Baxter International Inc., CPL Biologicals Pvt. Ltd., CSL Limited, GlaxoSmithKline Plc, MedImmune LLC., Novartis AG, Sanofi Pasteur SA, Simcere Pharmaceutical Group, Sinovac Biotech Ltd, Solvay SA, and Zydus Cadila.

View Full Report Details: http://www.companiesandmarkets.com/r.ashx?id=M6AIL461A289258&prk=c34cdcdbcee15ae68d55d5fb6c49c818